Dual Drug Delivery in Cancer Therapy Using Graphene Oxide-Based Nanoplatforms

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15640%2F24%3A73626110" target="_blank" >RIV/61989592:15640/24:73626110 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61989592:15110/24:73626110

Výsledek na webu

<a href="https://onlinelibrary.wiley.com/doi/10.1002/anbr.202400026" target="_blank" >https://onlinelibrary.wiley.com/doi/10.1002/anbr.202400026</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/anbr.202400026" target="_blank" >10.1002/anbr.202400026</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Dual Drug Delivery in Cancer Therapy Using Graphene Oxide-Based Nanoplatforms

Popis výsledku v původním jazyce

Many types of cancer are currently treated using a combination of chemotherapeutics, but unfortunately, this strategy is considerably limited by severe side effects. The current development of nanocarriers enables the use of multiple drugs anchored on one unique platform thus enhancing the initiated therapeutic effect and minimizing the possibility of drug resistance. In this context, a graphene-oxide-based 2D nanoplatform is developed, which is functionalized using highly branched polyethylene-glycol and a multimodal set of two drugs with various mechanisms of action, namely Pt-based complex (a Pt(IV) prodrugs based on cisplatin) and doxorubicin (DOX). We performed in vitro 2D screening on two cancer cell lines, namely glioblastoma and osteosarcoma, that were selected as models of two aggressive tumors that remain a massive challenge in oncology. The therapeutic effect of the developed nano-platform is higher at lower concentrations (15 mu m of Pt-drug, 0.6 mu m DOX) compared to the impact of the free drugs. This indicates a possible positive effect of the accumulation and transport of the drugs using this nanoplatform. Results obtained on 3D cell models using MG63 osteosarcoma cells uncovered an understandable lowered diffusion profile of the developed nanoplatforms, compared to the application of free drugs.

Název v anglickém jazyce

Dual Drug Delivery in Cancer Therapy Using Graphene Oxide-Based Nanoplatforms

Popis výsledku anglicky

Many types of cancer are currently treated using a combination of chemotherapeutics, but unfortunately, this strategy is considerably limited by severe side effects. The current development of nanocarriers enables the use of multiple drugs anchored on one unique platform thus enhancing the initiated therapeutic effect and minimizing the possibility of drug resistance. In this context, a graphene-oxide-based 2D nanoplatform is developed, which is functionalized using highly branched polyethylene-glycol and a multimodal set of two drugs with various mechanisms of action, namely Pt-based complex (a Pt(IV) prodrugs based on cisplatin) and doxorubicin (DOX). We performed in vitro 2D screening on two cancer cell lines, namely glioblastoma and osteosarcoma, that were selected as models of two aggressive tumors that remain a massive challenge in oncology. The therapeutic effect of the developed nano-platform is higher at lower concentrations (15 mu m of Pt-drug, 0.6 mu m DOX) compared to the impact of the free drugs. This indicates a possible positive effect of the accumulation and transport of the drugs using this nanoplatform. Results obtained on 3D cell models using MG63 osteosarcoma cells uncovered an understandable lowered diffusion profile of the developed nanoplatforms, compared to the application of free drugs.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

20903 - Bioproducts (products that are manufactured using biological material as feedstock) biomaterials, bioplastics, biofuels, bioderived bulk and fine chemicals, bio-derived novel materials

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

ADVANCED NANOBIOMED RESEARCH

ISSN

2699-9307

e-ISSN

2699-9307

Svazek periodika

4

Číslo periodika v rámci svazku

9

Stát vydavatele periodika

DE - Spolková republika Německo

Počet stran výsledku

10

Strana od-do

—

Kód UT WoS článku

001226029700001

EID výsledku v databázi Scopus

2-s2.0-85193351241